330 related articles for article (PubMed ID: 30513486)
1. The impact of pharmaceutical tendering on prices and market concentration in South Africa over a 14-year period.
Wouters OJ; Sandberg DM; Pillay A; Kanavos PG
Soc Sci Med; 2019 Jan; 220():362-370. PubMed ID: 30513486
[TBL] [Abstract][Full Text] [Related]
2. Competition in the off-patent medicine market in Spain: The national reference pricing system versus the regional system of tendering for outpatient prescription medicines in Andalusia.
Casanova-Juanes J; Mestre-Ferrandiz J; Espín-Balbino J
Health Policy; 2018 Dec; 122(12):1310-1315. PubMed ID: 30389186
[TBL] [Abstract][Full Text] [Related]
3. Pseudo-Generics in South Africa: A Price Comparison.
Bangalee V; Suleman F
Value Health Reg Issues; 2019 Sep; 19():87-91. PubMed ID: 31357098
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of prices, availability and affordability of essential medicines in Lahore Division, Pakistan: A cross-sectional survey using WHO/HAI methodology.
Saeed A; Saeed H; Saleem Z; Fang Y; Babar ZU
PLoS One; 2019; 14(4):e0216122. PubMed ID: 31022276
[TBL] [Abstract][Full Text] [Related]
5. Access and Affordability of Medicines in Malaysia: Need for a National Pricing Policy.
Wong SL; Ibrahim S; Abdul Kadir N; Mohd Salleh S
Appl Health Econ Health Policy; 2019 Oct; 17(5):641-654. PubMed ID: 31093937
[TBL] [Abstract][Full Text] [Related]
6. Availability, prices and affordability of essential medicines for children: a cross-sectional survey in Jiangsu Province, China.
Sun X; Wei J; Yao Y; Chen Q; You D; Xu X; Dai J; Yao Y; Sheng J; Li X
BMJ Open; 2018 Oct; 8(10):e023646. PubMed ID: 30341137
[TBL] [Abstract][Full Text] [Related]
7. Pricing policies for generic medicines in Australia, New Zealand, the Republic of Korea and Singapore: patent expiry and influence on atorvastatin price.
Roughead EE; Kim DS; Ong B; Kemp-Casey A
WHO South East Asia J Public Health; 2018 Sep; 7(2):99-106. PubMed ID: 30136668
[TBL] [Abstract][Full Text] [Related]
8. Prices, availability and affordability of medicines in Rwanda.
Bizimana T; Kayumba PC; Heide L
PLoS One; 2020; 15(8):e0236411. PubMed ID: 32745100
[TBL] [Abstract][Full Text] [Related]
9. The impact of the single exit price policy on a basket of generic medicines in South Africa, using a time series analysis from 1999 to 2014.
Moodley R; Suleman F
PLoS One; 2019; 14(7):e0219690. PubMed ID: 31365534
[TBL] [Abstract][Full Text] [Related]
10. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis.
Cameron A; Ewen M; Ross-Degnan D; Ball D; Laing R
Lancet; 2009 Jan; 373(9659):240-9. PubMed ID: 19042012
[TBL] [Abstract][Full Text] [Related]
11. Prices & availability of common medicines at six sites in India using a standard methodology.
Kotwani A; Ewen M; Dey D; Iyer S; Lakshmi PK; Patel A; Raman K; Singhal GL; Thawani V; Tripathi S; Laing R
Indian J Med Res; 2007 May; 125(5):645-54. PubMed ID: 17642500
[TBL] [Abstract][Full Text] [Related]
12. The prices people pay for medicines in Zimbabwe.
Gavaza P; Simoyi T; Makunike B; Maponga CC
Cent Afr J Med; 2009; 55(1-4):14-9. PubMed ID: 21977842
[TBL] [Abstract][Full Text] [Related]
13. The 'Netflix plus model': can subscription financing improve access to medicines in low- and middle-income countries?
Cherla A; Howard N; Mossialos E
Health Econ Policy Law; 2021 Apr; 16(2):113-123. PubMed ID: 32122423
[TBL] [Abstract][Full Text] [Related]
14. [Availability of generic drugs in the public sector and prices in the private sector in different regions of Brazil].
Miranda ES; Pinto Cdu B; dos Reis AL; Emmerick IC; Campos MR; Luiza VL; Osorio-de-Castro CG
Cad Saude Publica; 2009 Oct; 25(10):2147-58. PubMed ID: 19851615
[TBL] [Abstract][Full Text] [Related]
15. Access to affordable medicines after health reform: evidence from two cross-sectional surveys in Shaanxi Province, western China.
Fang Y; Wagner AK; Yang S; Jiang M; Zhang F; Ross-Degnan D
Lancet Glob Health; 2013 Oct; 1(4):e227-37. PubMed ID: 25104348
[TBL] [Abstract][Full Text] [Related]
16. An improved maize marketing system for African countries: the case of Zimbabwe.
Child B; Muir K; Blackie M
Food Policy; 1985 Nov; 10(4):365-73. PubMed ID: 12280292
[TBL] [Abstract][Full Text] [Related]
17. Inflated medicine prices in Vietnam: a qualitative study.
Nguyen TA; Knight R; Mant A; Razee H; Brooks G; Dang TH; Roughead EE
Health Policy Plan; 2017 Jun; 32(5):647-656. PubMed ID: 28453716
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the impact of single exit pricing (SEP) on medicine product withdrawal from the private healthcare market in South Africa.
Naidoo K; Suleman F
S Afr Med J; 2021 Apr; 111(5):444-447. PubMed ID: 34852886
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the impact of the single exit price policy on a basket of originator medicines in South Africa from 1999 to 2014 using a time series analysis.
Moodley R; Suleman F
BMC Health Serv Res; 2019 Aug; 19(1):576. PubMed ID: 31419977
[TBL] [Abstract][Full Text] [Related]
20. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
Mansfield SJ
Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
